Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
Larimar Therapeutics, Inc. will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York from November 6-7, 2023. The fireside chat will take place on November 7, 2023, from 1:10 - 1:40 PM ET. A replay of the chat will be available on Larimar's website for 30 days.
11/01/2023 - 04:05 PM
BALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference, taking place in New York, NY from November 6 - 7, 2023.
Details on the fireside chat can be found below.
Date: Tuesday, November 7, 2023 Time: 1:10 – 1:40 PM ET Webcast Link: https://guggenheim.metameetings.net/events/ini23
Following the conclusion of the fireside chat, a replay will be available for 30 days on the “Events and Presentations ” page of Larimar’s website.
About Larimar Therapeutics Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com .
Investor Contact: Joyce Allaire LifeSci Advisors jallaire@lifesciadvisors.com (212) 915-2569
Company Contact: Michael Celano Chief Financial Officermcelano@larimartx.com (484) 414-2715
What is Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
What is the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference?
The Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference is an event where industry professionals gather to discuss advancements and developments in the field of inflammation, neurology, and immunology.
When will Larimar Therapeutics participate in the fireside chat?
Larimar Therapeutics will participate in the fireside chat on Tuesday, November 7, 2023, from 1:10 - 1:40 PM ET.
Where can I watch the fireside chat?
The fireside chat can be watched through the webcast link: https://guggenheim.metameetings.net/events/ini23.
Will there be a replay of the fireside chat?
Yes, a replay of the fireside chat will be available on Larimar's website for 30 days.
LRMR Rankings
#3294 Ranked by Stock Gains
LRMR Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Pharmaceuticals: Major, Commercial Services, Miscellaneous Commercial Services, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Bala Cynwyd
About LRMR
larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.